Alzheimer’s disease (AD) is a progressive neurological disorder that stands as one of the foremost causes of dementia across the globe. Despite extensive research efforts, a definitive cure remains elusive. Recently, novel antibody-based therapies targeting amyloid β (Aβ) have surfaced, yet their efficacy has been subdued. Additionally, these treatments can incur significant costs and may lead to immune-related side effects, highlighting the critical need for safer and more affordable alternatives to mitigate the disease’s progression.
A recent study published in Neurochemistry International uncovers a promising avenue. Researchers from Kindai University and collaborating institutions discovered that arginine, a naturally occurring amino acid, can effectively curb the accumulation of harmful Aβ proteins in animal models of Alzheimer’s. Furthermore, arginine functions as a safe chemical chaperone, aiding proteins in maintaining their correct structure.
The research team, which included Graduate Student Kanako Fujii and Professor Yoshitaka Nagai from the Department of Neurology at Kindai University Faculty of Medicine in Osaka, and Associate Professor Toshihide Takeuchi from the Life Science Research Institute at Kindai University, emphasized that while arginine is readily available as an over-the-counter supplement, the dosages and methods employed in their study were tailored specifically for research purposes, differing from commercial products.
Lab and Animal Studies Show Strong Effects
In lab experiments, the scientists initially demonstrated that arginine could inhibit the formation of Aβ42 aggregates, which are particularly toxic. This effect intensified with increasing concentrations of arginine.
Subsequently, they administered oral arginine in two well-established Alzheimer’s models:
- A Drosophila model expressing Aβ42 with the Arctic mutation (E22G)
- An AppNL-G-F knock-in mouse model featuring three familial AD mutations
In both instances, arginine treatment not only decreased the accumulation of Aβ but also alleviated its detrimental impacts.
“Our study shows that arginine can inhibit Aβ aggregation both in vitro and in vivo,” states Prof. Nagai. “The exciting aspect of this finding is that arginine is already established as clinically safe and inexpensive, making it a promising candidate for repositioning as a therapeutic option for AD.”
Improved Brain Health and Reduced Inflammation
In the mouse model, the advantages extended beyond just reducing protein accumulation. Arginine diminished amyloid plaque levels and lowered the amount of insoluble Aβ42 in the brain. Additionally, the treated mice exhibited enhanced performance in behavioral assessments.
The researchers observed that arginine decreased the activity of genes associated with pro-inflammatory cytokines, which are linked to neuroinflammation—a significant characteristic of Alzheimer’s disease. This finding suggests that arginine might not only impede the aggregation of harmful proteins but also offer broader protection to brain cells.
“Our results pave the way for developing arginine-based approaches for neurodegenerative diseases driven by protein misfolding and aggregation,” notes Prof. Nagai. “Given its excellent safety profile and economical nature, arginine could quickly transition into clinical trials for Alzheimer’s and possibly other related conditions.”
A Low-Cost Path Toward New Alzheimer’s Treatments
This study underscores the rising interest in drug repositioning, which entails discovering new applications for existing, well-established compounds. Since arginine is already clinically utilized in Japan and has been shown to safely penetrate the brain, it could circumvent some early obstacles that typically hinder traditional drug development.
Nonetheless, the researchers advise that further investigation is essential. Additional preclinical and clinical studies are necessary to ascertain whether these findings can be replicated in humans and to determine optimal dosing strategies.
Despite this, the findings furnish strong preliminary evidence that straightforward nutritional or pharmacological approaches may assist in reducing amyloid accumulation and enhancing brain function.
Expanding Understanding of Alzheimer’s Biology
In addition to its potential therapeutic role, this research sheds new light on the formation and accumulation of Aβ proteins in the brain. It also suggests a practical and cost-effective strategy that could ultimately benefit millions affected by Alzheimer’s worldwide.
Professor Yoshitaka Nagai, a neurologist and Chair of the Department of Neurology at Kindai University Faculty of Medicine in Osaka, specializes in neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis. His research focuses on protein misfolding and RNA-related mechanisms, and he has received multiple accolades from prominent organizations such as the Japanese Society of Neurochemistry and the Japanese Dementia Society.
This research was supported by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) (Grant No. 20H05927), Japan Society for the Promotion of Science (JSPS) (Grant Nos. 24H00630, 21H02840, 22H02792, and 25K02432), Japan Science and Technology Agency (JST) Super-Highway Program (SHW2023-03), and the National Center of Neurology and Psychiatry.
In conclusion, the intriguing findings from this research on arginine open up novel avenues for treating Alzheimer’s disease. With its already established safety and affordability, arginine presents an exciting opportunity for future clinical exploration, having the potential to make a significant impact in the fight against this challenging disease.
